Wellbutrin SR contains bupropion as its active component. It belongs to the class of antidepressants and is also used in addiction recovery, particularly for smoking cessation. The medication is supplied as a pill in a 150 mg strength. In Hong Kong, Wellbutrin SR is a prescription-only product regulated by the Department of Health under the Pharmacy and Poisons Ordinance.
Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor (NDRI). By blocking the reabsorption of norepinephrine and dopamine in neuronal synapses, it increases the levels of these neurotransmitters in the brain. Higher norepinephrine and dopamine activity can improve mood, increase energy, and reduce cravings for nicotine. The sustained-release (SR) formulation allows the drug to be released gradually, providing a smoother onset of action and reducing the likelihood of peak-related side effects. Typical therapeutic effects begin within the first week, with full benefit often observed after several weeks of consistent use.
Wellbutrin SR is approved in Hong Kong for the following indications:
These indications are supported by regulatory review and clinical trial evidence demonstrating improvement in mood scores and increased abstinence rates for smokers.
Wellbutrin SR has been studied for several off-label uses, including:
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
These effects are generally mild and tend to improve with continued therapy.
Patients should inform their healthcare provider of all medications, supplements, and herbal products before starting Wellbutrin SR.
This article provides educational information about Wellbutrin SR and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Bupropion’s stimulant effect can be enhanced by caffeine, potentially leading to increased nervousness or insomnia. Moderate caffeine intake is generally acceptable, but patients should monitor how they feel and reduce caffeine if side effects worsen.
“SR” indicates a sustained-release formulation that slowly releases bupropion over several hours, providing steadier blood levels and reducing peak-related side effects compared with immediate-release tablets.
Yes, the Department of Health in Hong Kong has approved Wellbutrin SR for major depressive disorder, seasonal affective disorder, and smoking cessation under a prescription-only status.
Patients often notice some improvement within the first week, but full therapeutic effects may take 4-6 weeks of consistent dosing.
Weight loss is a reported side effect, likely due to appetite suppression. Individuals experiencing significant weight changes should discuss the issue with their provider.
Seek emergency medical attention immediately. Inform the healthcare team about the seizure, as dose adjustment or discontinuation may be necessary.
Older adults should start at the lowest possible dose (150 mg) and be monitored closely for insomnia, dizziness, and blood pressure changes.
Wellbutrin SR is classified as a Category C medication in many jurisdictions, indicating that risk cannot be ruled out. The decision to use it during pregnancy must be made by a specialist after weighing potential benefits and risks.
Most patients do not experience significant impairment, but dizziness or insomnia may affect alertness. Caution is advised until the individual knows how the medication affects them.
Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion primarily influences dopamine and norepinephrine, which may result in fewer sexual side effects and a lower risk of weight gain. However, individual response varies, and selection should be personalized.
